Journal article
Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1–3 metastases
Abstract
Abstract We examined functional outcomes and quality of life of whole brain radiotherapy (WBRT) with integrated fractionated stereotactic radiotherapy boost (FSRT) for brain metastases treatment. Eighty seven people with 1–3 brain metastases (54/87 lung primary, 42/87 single brain metastases) were enrolled on this Phase II trial of WBRT (30 Gy/10) + simultaneous FSRT, (60 Gy/10). Median overall follow-up and survival was 5.4 months, 6 month …
Authors
Bauman G; Yartsev S; Roberge D; MacRae R; Roa W; Panet-Raymond V; Masucci L; Yaremko B; D’Souza D; Palma D
Journal
Journal of Neuro-Oncology, Vol. 128, No. 3, pp. 431–436
Publisher
Springer Nature
Publication Date
7 2016
DOI
10.1007/s11060-016-2128-7
ISSN
0167-594X